In another study, post-treatment intratumoral B cell counts and B cell associated gene signatures strongly correlated with response to anti-PD-1 +/- anti-CTLA-4 in locally advanced melanoma patients exposed to neoadjuvant ICI therapy, whilst B cell counts at baseline did not [165]. This evidence concerns the gene PDCD1 and melanoma.